Parisa Zamiri - Mar 23, 2023 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role: Chief Medical Officer
Signature: /s/ Robert S. Breuil, Attorney-in-Fact
Stock symbol: CALC
Transactions as of: Mar 23, 2023
Transactions value $: -$98,456
Form type: 4
Date filed: 3/27/2023, 07:59 PM
Previous filing: Mar 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CALC	Common Stock	Disposed to Issuer		+42.8K	+1040.15%		46.9K	Mar 23, 2023	Direct	F1, F2
transaction	CALC	Common Stock	Tax liability	-$98.5K	-17.9K	-38.18%	$5.50	29K	Mar 23, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CALC	Restricted Stock Unit	Disposed to Issuer		-42.8K	-100%		0	Mar 23, 2023	Common Stock	42.8K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.
F2	Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023.

Content

Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023.